Table 1.
Demographics of patients seen for hydroxychloroquine screening.
| Patients on HCQ (n = 166) | |
|---|---|
| Sex | |
| Female (%) | 150 (90.4%) |
| Male (%) | 16 (9.6%) |
| Race | |
| Asian (%) | 24 (14.5%) |
| Black or African American (%) | 7 (4.2%) |
| Other or mixed race (%) | 50 (30.1%) |
| Unknown (%) | 4 (2.4%) |
| White (%) | 81 (48.8%) |
| Estimated age starting HCQ in years | |
| Mean (CI) | 44.2 (41.7, 46.8) |
| Weight in kg | |
| Mean (CI) | 71.7 (68.9, 74.6) |
| Duration of therapy in years | |
| Mean (CI) | 5.3 (4.4, 6.1) |
| Estimated daily dose in mg/kg | |
| Mean (CI) | 5.2 (5.0, 5.5) |
| Cumulative dose in grams | |
| Mean (CI) | 684.4 (568.5, 800.4) |
| High-riska | |
| No (%) | 110 (66.7%) |
| Yes (%) | 55 (33.3%) |
| SD-OCT screen | |
| No (%) | 7 (4.2%) |
| Yes (%) | 159 (95.8%) |
| FAF screen | |
| No (%) | 18 (10.8%) |
| Yes (%) | 148 (89.2%) |
| HVF screen | |
| No (%) | 47 (28.3%) |
| Yes (%) | 119 (71.7%) |
HCQ Hydroxychloroquine, SD-OCT Spectral-domain optical coherence tomography, FAF Fundus autofluorescence, HVF Humphrey visual field.
aHigh-risk features including renal disease, concomitant tamoxifen use, known retinal or macular disease.